The safety-code card is a pocket card that is handed out to all patients assigned to the study group and that contains a quick overview of his or her PGx test results. Furthermore, the card contains a QR code that can be scanned by healthcare providers with, e.g., a smartphone to quickly retrieve PGx-based dosing recommendations relevant to the respective patient. In the context of PREPARE, the safety-code card serves as an auxiliary tool to maximize the accessibility and sharing of PGx results within and between different healthcare settings and healthcare professionals. For more information on the safety-code card, please visit http://www.safety-code.org.
In the PREPARE study, pharmacogenomic dosing guidelines authored by the Dutch Pharmacogenetics Working Group (DPWG) are used for PGx-based prescribing. To assist healthcare providers in using their patients’ PGx results to optimize their therapy, all recommendations relevant to the individual patient are included in the their written PGx report. Furthermore, all relevant recommendations can be accessed by healthcare providers via scanning the QR code of the personal safety-code card that each patient assigned to the study group receives.
Patients are asked to provide a blood or saliva sample which is analyzed for over 40 variants across 13 important PGx genes. Genotyping is performed with an array specifically designed for the PREPARE study using the LGC SNPline platform.
|Therapeutic group||Generic name|
|Cholesterol – lowering||Atorvastatin|
|Immuno – suppressive||Azathioprine|
|Oestrogen containing drugs *|
* only if a 2nd prescription, not for primary inclusion
Patients who receive a first prescription for any of the drugs relevant to the study during their treatment at one of the participating institutions and who fulfill all other inclusion criteria are contacted by their local study teams.
What is the study design of PREPARE?
PREPARE is designed as a multi-center, open, randomized, cross-over study. The sequence of study and control arm is randomized per country to minimize the influence of time dependent variables.
The 7 participating countries were randomized to start with:
1) Implementing pre-emptive PGx testing to guide drug and dose selection (study arm): Greece, Slovenia and Spain
2) Providing standard clinical care (control arm): Netherlands, Austria, Italy and UK